AXL signaling increased renal cell carcinoma expression of the pro-angiogenic factor S100A10, and an AXL inhibitor combined with a VEGF inhibitor decreased the growth of patient-derived xenografts and vessel density in mice [32]. This evidence concerns the gene S100A10 and hereditary clear cell renal cell carcinoma.